These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Newly approved therapies for RCC and their effect on the standard of care. Figlin RA Clin Adv Hematol Oncol; 2007 Jan; 5(1):35-6, 66. PubMed ID: 17339824 [No Abstract] [Full Text] [Related]
5. New therapeutic approaches in the management of metastatic renal cell carcinoma. Gkialas IK; Papadopoulos G J BUON; 2009; 14(3):399-404. PubMed ID: 19810129 [TBL] [Abstract][Full Text] [Related]
6. Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab. Garcia JA; Hutson TE; Elson P; Cowey CL; Gilligan T; Nemec C; Dreicer R; Bukowski RM; Rini BI Cancer; 2010 Dec; 116(23):5383-90. PubMed ID: 20806321 [TBL] [Abstract][Full Text] [Related]
7. Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies. Chowdhury S; Larkin JM; Gore ME Eur J Cancer; 2008 Oct; 44(15):2152-61. PubMed ID: 18829302 [TBL] [Abstract][Full Text] [Related]
8. Treatment options in renal cell carcinoma: past, present and future. Oudard S; George D; Medioni J; Motzer R Ann Oncol; 2007 Sep; 18 Suppl 10():x25-31. PubMed ID: 17761720 [TBL] [Abstract][Full Text] [Related]
9. Update on systemic therapies of metastatic renal cell carcinoma. Herrmann E; Bierer S; Wülfing C World J Urol; 2010 Jun; 28(3):303-9. PubMed ID: 20180125 [TBL] [Abstract][Full Text] [Related]
10. Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence. Hutson TE Oncologist; 2011; 16 Suppl 2(Suppl 2):14-22. PubMed ID: 21346036 [TBL] [Abstract][Full Text] [Related]
11. [Angiogenesis inhibition: review of the activity of sorafenib, sunitinib and bevacizumab]. Barrascout E; Medioni J; Scotte F; Ayllon J; Mejean A; Cuenod CA; Tartour E; Elaidi R; Oudard S Bull Cancer; 2010; 97():29-43. PubMed ID: 20418202 [TBL] [Abstract][Full Text] [Related]